PharmAust Successfully produces smaller GMP tablets
- PharmAust’s (PAA) upcoming human trials receives a major boost as the company’s GMP monepantel (MPL) tablets has been produced at a smaller size
- A total of 2000 smaller tablets were successfully produced using the same process as the larger tablets
- The smaller tablets are for the upcoming trials of motor neuron disease (MND) and COVID-19 clinical trials are underway
- The GMP tablet manufacturing is on schedule for February 2022
- The company is down 1.02 per cent and trading at 9.7 cents per share
